DENVER–(BUSINESS WIRE)–EvoEndo®, Inc. (“EvoEndo”), a medical device company which developed a single use system that allows for unsedated Transnasal Endoscopy (TNE), has announced the completion of an $8.4 million Series A financing round led by founding investor TLP Investment Partners LLC (TLP) and including the Sunshine Charitable Foundation and the Jill and Paul Meister family. Proceeds from the financing will be used to support the initial commercial launch of the EvoEndo® Single-Use Endoscopy System by hiring additional personnel and growing inventory capacity. The company will also deploy the funding to conduct clinical and post-market surveillance studies.
Trending
- OneOncology and OpenEvidence Partner to Improve Cancer Care Nationwide (OneOncology)
- FIT-Based Screening Linked to Drop in Colorectal Cancer Mortality (Medpage Today)
- Vedanta Biosciences Secures $60 Million in Funding and Strengthens Leadership Team Ahead of Pivotal Phase 3 Data (Business Wire)
- The physician opportunity cost nobody puts on a bill (KevinMD)
- A ‘molecular switch’ that heals the gut—and that colorectal cancer hijacks to spread (Medical Xpress)
- Why gastroenterology is especially exposed to predatory contracts, GI says (Becker’s GI & Endoscopy)
- The Microbiome Is Not a Bar Code
- Not All False-Positive Stool DNA Tests Should be Dismissed (GI & Endoscopy News)
